- Trials with a EudraCT protocol (38)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
38 result(s) found for: Chlorambucil.
Displaying page 1 of 2.
EudraCT Number: 2004-000440-24 | Sponsor Protocol Number: SDX-101-03 | Start Date*: 2004-08-24 |
Sponsor Name:Cephalon UK Limited | ||
Full Title: A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination with Chlorambucil, and that of Chlorambucil alone, in Patients with Chronic ... | ||
Medical condition: Chronic Lymphocytic Leukemia (CLL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000172-16 | Sponsor Protocol Number: MO20927 | Start Date*: 2007-08-24 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia. | ||
Medical condition: CD20-positive B-cell chronic lymphocytic leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004932-19 | Sponsor Protocol Number: OMB110911 | Start Date*: 2009-01-27 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SE (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004551-20 | Sponsor Protocol Number: GS-US-312-0118 | Start Date*: 2015-07-02 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Un... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) HU (Completed) ES (Completed) BE (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005582-73 | Sponsor Protocol Number: ACE-CL-007 | Start Date*: 2015-07-03 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previ... | |||||||||||||
Medical condition: Untreated Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012476-28 | Sponsor Protocol Number: BO21004 | Start Date*: 2010-02-24 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone ... | |||||||||||||
Medical condition: Patients with previously untreated B-CLL with comorbidities. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) NL (Completed) RO (Completed) SK (Completed) DK (Completed) IT (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003079-32 | Sponsor Protocol Number: CC-5013-CLL-008 | Start Date*: 2009-06-19 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LÍNEA EN PA... | |||||||||||||
Medical condition: TERAPIA DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B NO TRATADOS PREVIAMENTE (FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRON... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005758-36 | Sponsor Protocol Number: UTX-TGR-304 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:TG Therapeutics | |||||||||||||
Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001810-24 | Sponsor Protocol Number: BO25323 | Start Date*: 2014-12-17 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND ... | |||||||||||||
Medical condition: chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) EE (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004896-38 | Sponsor Protocol Number: IELSG38 | Start Date*: 2014-02-13 | |||||||||||
Sponsor Name:IELSG (International Extranodal Lymphoma Study Group) | |||||||||||||
Full Title: A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF ... | |||||||||||||
Medical condition: Patients with MALT Lymphoma treated with chlorambucil and rituximab followed by maintenance treatment with subcutaneous rituximab | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003968-44 | Sponsor Protocol Number: PCYC-1116-CA | Start Date*: 2013-02-05 | |||||||||||
Sponsor Name:Pharmacyclics LLC | |||||||||||||
Full Title: An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlo... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IE (Completed) CZ (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003967-23 | Sponsor Protocol Number: PCYC-1115-CA | Start Date*: 2013-02-05 | |||||||||||
Sponsor Name:Pharmacyclics, Incorporated | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic L... | |||||||||||||
Medical condition: Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002069-31 | Sponsor Protocol Number: PCYC-1130-CA | Start Date*: 2014-11-11 | ||||||||||||||||
Sponsor Name:Pharmacyclics LLC | ||||||||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Sub... | ||||||||||||||||||
Medical condition: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) IT (Completed) CZ (Completed) AT (Completed) BE (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002949-42 | Sponsor Protocol Number: PACT-29 | Start Date*: 2020-11-27 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing a germ line BRCA or other DNA Defects Repair (DDR) mutations. | |||||||||||||
Medical condition: Patients affected by metastatic pancreatic adenocarcinoma (PDAC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004699-77 | Sponsor Protocol Number: 54179060CLL3011 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leuke... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003495-35 | Sponsor Protocol Number: IEO S311/306 | Start Date*: 2007-06-05 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: PHASE II TRIAL OF BORTEZOMIB (VELCADE) IN COMBINATION WITH CHLORAMBUCIL IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTROMムS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA. A MULTICENTER STUDY. | |||||||||||||
Medical condition: WALDENSTROMムS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000919-22 | Sponsor Protocol Number: OMB114578 | Start Date*: 2011-09-14 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000860-28 | Sponsor Protocol Number: 02CLLIII | Start Date*: 2004-12-02 | |||||||||||
Sponsor Name:ribosepharm GmbH | |||||||||||||
Full Title: PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY | |||||||||||||
Medical condition: Hematopoietic insufficiency with non-hemolysis-induced Hb <10 g/dL Thrombocytopenia <100x109/L (equivalent to Binet stage C) B symptoms Rapidly progressive disease (such as rapid lymphoma growth, r... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001612-20 | Sponsor Protocol Number: ML21445 | Start Date*: 2008-05-29 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: A study of chlorambucil plus MabThera as induction therapy followed in responders by maintenance therapy versus observation on response rate in patients ≥ 60 years with previously untreated ... | |||||||||||||
Medical condition: CD20+ CLL, Binet stage C or Binet stages A-B | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012072-28 | Sponsor Protocol Number: MO22468 | Start Date*: 2009-11-23 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: Estudio randomizado en fase IIIb de MabThera® (rituximab) agregado a quimioterápia, bendamustina o clorambucilo, en pacientes con leucemia linfática crónica. A randomized Phase IIIb study of MabTh... | |||||||||||||
Medical condition: Pacientes con leucemia linfática crónica (LLC) en primera linea o segunda línea (máximo de una línea de tratamiento previa) con necesidad de tratamiento. (En España, solo se incluirán pacientes en ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SE (Completed) FR (Completed) FI (Completed) PT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
